Titrating graft-versus-host disease: Is it worth a try?

Bone Marrow Transplantation

Volumn 38, Issue 10, 2006, Pages 653-656

  Akpek, G ^a,b  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CORTICOSTEROID; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ALLOGENIC BONE MARROW TRANSPLANTATION; BONE MARROW TRANSPLANTATION; CANCER RELAPSE; CHRONIC MYELOID LEUKEMIA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; HYPOTHESIS; IMMUNOSUPPRESSIVE TREATMENT; INDIVIDUALIZATION; LEUKEMIA RELAPSE; MEDICAL DECISION MAKING; MORTALITY; MUCOSA INFLAMMATION; MYELOABLATIVE CONDITIONING; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; TREATMENT FAILURE; TREATMENT PLANNING;

BONE MARROW TRANSPLANTATION; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 33750535633     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705504     Document Type: Review

References (22)

1. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
2. Ringden O, Hermans J, Labopin M, Apperley J, Gorin NC, Gratwohl A. The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease. Acute and Chronic Leukaemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT). Leuk Lymphoma 1996; 24: 71-79.
3. Uphoff DE. Graft versus host reaction modified by in vitro marrow-erythrocyte preincubation. Nature 1969; 222: 1089-1090.
4. Flowers ME, Kansu E, Sullivan KM. Pathophysiology and treatment of graft-versus-host disease. Hematol Oncol Clin North Am 1999; 13: 1091-1112.
5. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991; 324: 667-674.
6. Chao NJ, Chen BJ. Prophylaxis and treatment of acute graft-versus-host disease. Semin Hematol 2006; 43: 32-41.
7. Deeg HJ, Lin D, Leisenring W, Boeckh M, Anasetti C, Appelbaum FR et al. Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: A prospective, randomized trial. Blood 1997; 89: 3880-3887.
8. Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96: 2062-2068.
9. Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998; 92: 2303-2314.
10. Mielcarek M, Martin PJ, Leisenring W, Flowers ME, Maloney DG, Sandmaier BM et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102: 756-762.
11. Burroughs L, Mielcarek M, Leisenring W, Sandmaier BM, Maloney DG, Baron F et al. Extending postgrafting cyclosporine decreases the risk of severe graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation. Transplantation 2006; 81: 818-825.
12. Antin JH, Kim HT, Cutler C, Ho VT, Lee SJ, Miklos DB et al. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood 2003; 102: 1601-1605.
13. Bacigalupo A, Van Lint MT, Occhini D, Gualandi F, Lamparelli T, Sogno G et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 1991; 77: 1423-1428.
14. Devine SM, Geller RB, Lin LB, Dix SP, Holland HK, Maurer D et al. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 1997; 3: 25-33.
15. Porter DL, Roth MS, McGarigle C, Ferrara JL, Antin JH. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 1994; 330: 100-106.
16. Baron F, Beguin Y. Preemptive cellular immunotherapy after T-cell-depleted allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002; 8: 351-359.
17. Huff CA, Fuchs EJ, Smith BD, Blackford A, Garrett-Mayer E, Brodsky RA et al. Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. Biol Blood Marrow Transplant 2006; 12: 414-421.
18. Lokhorst HM, Wu K, Verdonck LF, Latereer LL, van de Dork NW, van Oers MH et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 2004; 103: 4362-4364.
19. Luft T, Moos M, Goldschmidt H, Ho AD, Gorner M. Dissociation of putative graft-versus-haematopoiesis and graft-versus-myeloma effects in patients with rapidly progressive multiple myeloma. Br J Haematol 2003; 123: 646-653.
20. Bleakley M, Riddell SR. Molecules and mechanisms of the graft-versus-leukemia effect. Nat Rev Cancer 2004; 4: 371-380.
21. Schmitz N, Barrett J. Optimizing engraftment - source and dose of stem cells. Semin Hematol 2002; 39: 3-14.
22. Barrett AJ, Rezvani K, Solomon S, Dickinso AM, Wang XN, Stark G et al. New developments in allotransplant immunology. Hematology (Am Soc Hematol Educ Program) 2003; 350-371.